Compare Freshworks Inc (FRSH) vs Organon & Co. Common Stock (OGN) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Freshworks Inc vs Organon & Co. Common Stock — how do they compare? Freshworks Inc trades at $13.69 (market cap $3.57B), while Organon & Co. Common Stock trades at $13.73 (market cap $3.61B). The key difference: Freshworks Inc and Organon & Co. Common Stock are close in size by market cap, and Organon & Co. Common Stock pays a 0.58% dividend while Freshworks Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Freshworks Inc for 40 Days and Organon & Co. Common Stock for 0 Days on average.
| FRSH | OGN | |
|---|---|---|
Market Cap | $3.57B | $3.61B |
Volume | 4,701,335 | 1,808,049 |
Sector | Technology | Health |
52-Week High | $13.92 | $13.81 |
52-Week Low | $6.88 | $5.70 |
Typical Hold Time | 40 Days | 0 Days |
Enterprise Value | $2.94B | $11.03B |
Dividend Yield | — | 0.58% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Freshworks (FRSH) trades at $13.90, down 0.14% with a bullish technical outlook. The company achieved its first GAAP profitability in Q2 2026, beating earnings expectations with $0.17 EPS versus $0.13 expected. Revenue growth remains strong at 16% YoY, with improving margins and positive cash flow trends. Analyst consensus is evenly split between Buy and Hold ratings with a $14.60 price target.
FRSH presents a compelling growth story with accelerating profitability and AI-driven product expansion. Key risks include competitive pressures in the SaaS sector and execution challenges in enterprise market penetration. The stock's current valuation at 22x P/E appears reasonable given the company's growth trajectory and improving financial metrics.
Organon (OGN) trades at $13.77, showing no change in the latest session. The stock demonstrates strong profitability with 52.68% gross margins and 24.04% ROE, though recent quarterly earnings have missed expectations. Valuation appears reasonable with P/E of 17.65 and P/S of 0.59. The company shows positive cash flow trends with 2026 projections indicating $533M net cash flow. Recent FDA developments for MIUDELLA and VTAMA products highlight ongoing pipeline progress.
OGN presents a mixed outlook with solid fundamentals offset by earnings misses. The healthcare company's improving cash flow and product pipeline offer potential upside, but investor sentiment remains divided with analysts showing cautious optimism. Key risks include execution challenges and competitive pressures in the pharmaceutical sector.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Freshworks Inc
Freshworks Inc provides software as a service platform that enables small and medium-sized businesses to support customers through e-mail, phone, website, and social networks. It offers solutions that serve the needs of users in the CX and ITSM categories, and have also expanded its offering with Sales and Marketing automation products. These product offerings enable organizations to acquire, engage, and better serve their customers and employees.
Read more on FRSH →About Organon & Co. Common Stock
Organon & Co. is a global healthcare company focused on women's health, biosimilars, and established brands, spun off from Merck & Co. in 2021. Its portfolio of more than 70 medicines includes contraception and fertility therapies, immunology and oncology biosimilars, and treatments in cardiovascular, respiratory, and dermatology, distributed in over 140 countries.
Read more on OGN →
